A Phase 3 interventional study of vedolizumab and Placebo in Crohn's Disease, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 41 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-07-21.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.
Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 5th largest by enrollment, is the only one that started in 2010, is one of 16 in phase 3, and was the 5th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Austria, Belgium and 23 more countries
Ages 18–65
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 416 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 101 across the 39 interventional studies. Of the 22 that completed or were terminated, 18 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
86 studies in Crohn Disease by Takeda: 12 open now, 14 under way, 7 of them phase 3. Of 66 finished, 37 (56%) have results posted.
Among the 86 studies in Crohn Disease by Takeda, this one is the 7th largest by enrollment of the 51 interventional ones that give a count, is the only one that started in 2010, is one of 25 in phase 3, and was the 8th registered.
Takeda’s Crohn Disease studies by the year they started, since 2000.
5 of the studies testing vedolizumab in Crohn Disease that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06045754TakedaA Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease | 2027-06-28 |
| NCT06180382Centre Hospitalier Universitaire de Saint EtienneComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 39 studies testing vedolizumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 86 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
This study in patients with moderately to severely active Crohn's disease is designed to establish the efficacy and safety of vedolizumab for the induction of clinical response and remission.
After completing the study, patients were eligible to enroll in a long term safety study with continued access to vedolizumab (study C13008; NCT00790933) if study drug was well tolerated, and no major surgical intervention for Crohn's disease occurred or was required.
Participants who did not enroll in Study C13008 were to complete the Final Safety visit (16 weeks after the last dose of study drug) for a maximum time on study of 22 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo intravenous infusion at Weeks 0, 2 and 6.
Other: Placebo
Participants received 300 mg intravenous vedolizumab at Weeks 0, 2, and 6.
Drug: vedolizumab
Vedolizumab for intravenous infusion
Also known as: Entyvio, MLN0002, MLN02, LDP-02
Placebo intravenous infusion
Percentage of Participants in Clinical Remission in the Tumor Necrosis Factor Alpha (TNFα) Antagonist Failure Subpopulation
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
Time frame: Week 6
Percentage of Participants in Clinical Remission at Week 6 in the Overall Population
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
Time frame: Week 6
Percentage of Participants in Clinical Remission at Week 10 in the TNFα Antagonist Failure Subpopulation
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
Time frame: Week 10
Percentage of Participants in Clinical Remission at Week 10 in the Overall Population
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
Time frame: Week 10
Percentage of Participants With Sustained Clinical Remission in the TNFα Antagonist Failure Population
Sustained clinical remission is defined as a CDAI score ≤ 150 points at both Week 6 and Week 10. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving sustained clinical remission.
Time frame: Week 6 and Week 10
Percentage of Participants With Sustained Clinical Remission in the Overall Population
Sustained clinical remission is defined as a CDAI score ≤ 150 points at both Week 6 and Week 10. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving sustained clinical remission.
Time frame: Week 6 and Week 10
Percentage of Participants With Enhanced Clinical Response at Week 6 in the TNFα Antagonist Failure Subpopulation
Enhanced clinical response is defined as a ≥ 100-point decrease in CDAI score from Baseline. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percent deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving enhanced clinical response.
Time frame: Baseline and Week 6
Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a patient administered a pharmaceutical product, which did not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was any AE, occurring at any dose and regardless of causality that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was an important medical event based upon appropriate medical judgment that may have jeopardized the patient and may have required medical or surgical intervention to prevent 1 of the outcomes listed above, or any diagnosis of progressive multifocal leukoencephalopathy (PML). Relationship to study drug administration was determined by the investigator responding yes or no to the question: Is there a reasonable possibility that the AE is associated with the study drug?
Time frame: From the date of first study drug administration to Week 22, through the 14 March 2012 database lock date. At the time of this database lock, 7 patients had completed Week 10 or early termination assessments but not Week 22 assessments.
Participants with moderately to severely active Crohn's Disease took part in the study at 107 sites worldwide from 24 November 2010 to 12 April 2012. Approximately 75% of participants were to have previously failed tumor necrosis factor alpha (TNFα) antagonist therapy and approximately 25% were to have been naïve to TNFα antagonist therapy.
| Milestone | Placebo | Vedolizumab |
|---|---|---|
| Started | 207 | 209 |
| Tnfα antagonist failure population | 157 | 158 |
| Completed | 192 | 196 |
| Not completed | 15 | 13 |
| Withdrew: Adverse event | 8 | 4 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Lack of efficacy | 5 | 1 |
| Withdrew: Withdrawal of consent | 2 | 4 |
| Withdrew: Lost to follow-up | 0 | 3 |
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
| percentage of participants | Placebo | Vedolizumab |
|---|---|---|
| Percentage of Participants in Clinical Remission in the Tumor Necrosis Factor Alpha (TNFα) Antagonist Failure Subpopulation | 12.1 (7.0 to 17.2) | 15.2 (9.6 to 20.8) |
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
| percentage of participants | Placebo | Vedolizumab |
|---|---|---|
| Percentage of Participants in Clinical Remission at Week 6 in the Overall Population | 12.1 (7.6 to 16.5) | 19.1 (13.8 to 24.5) |
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
| percentage of participants | Placebo | Vedolizumab |
|---|---|---|
| Percentage of Participants in Clinical Remission at Week 10 in the TNFα Antagonist Failure Subpopulation | 12.1 (7.0 to 17.2) | 26.6 (19.7 to 33.5) |
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
| percentage of participants | Placebo | Vedolizumab |
|---|---|---|
| Percentage of Participants in Clinical Remission at Week 10 in the Overall Population | 13.0 (8.5 to 17.6) | 28.7 (22.6 to 34.8) |
Sustained clinical remission is defined as a CDAI score ≤ 150 points at both Week 6 and Week 10. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving sustained clinical remission.
| percentage of participants | Placebo | Vedolizumab |
|---|---|---|
| Percentage of Participants With Sustained Clinical Remission in the TNFα Antagonist Failure Population | 8.3 (4.0 to 12.6) | 12.0 (7.0 to 17.1) |
Sustained clinical remission is defined as a CDAI score ≤ 150 points at both Week 6 and Week 10. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving sustained clinical remission.
| percentage of participants | Placebo | Vedolizumab |
|---|---|---|
| Percentage of Participants With Sustained Clinical Remission in the Overall Population | 8.2 (4.5 to 12.0) | 15.3 (10.4 to 20.2) |
Enhanced clinical response is defined as a ≥ 100-point decrease in CDAI score from Baseline. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percent deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving enhanced clinical response.
| percentage of participants | Placebo | Vedolizumab |
|---|---|---|
| Percentage of Participants With Enhanced Clinical Response at Week 6 in the TNFα Antagonist Failure Subpopulation | 22.3 (15.8 to 28.8) | 39.2 (31.6 to 46.9) |
An AE was defined as any untoward medical occurrence in a patient administered a pharmaceutical product, which did not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was any AE, occurring at any dose and regardless of causality that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was an important medical event based upon appropriate medical judgment that may have jeopardized the patient and may have required medical or surgical intervention to prevent 1 of the outcomes listed above, or any diagnosis of progressive multifocal leukoencephalopathy (PML). Relationship to study drug administration was determined by the investigator responding yes or no to the question: Is there a reasonable possibility that the AE is associated with the study drug?
| participants | Placebo | Vedolizumab |
|---|---|---|
| Any adverse event | 124 | 117 |
| Drug-related adverse event | 34 | 34 |
| Adverse event resulting in study discontinuation | 8 | 4 |
| Serious adverse event | 16 | 13 |
| Serious infection adverse event | 0 | 2 |
| Drug-related serious adverse event | 1 | 1 |
| Serious adverse event resulting in discontinuation | 5 | 4 |
| Death | 0 | 0 |
Collected over From the date of first study drug administration to Week 22, through the 14 March 2012 database lock date. At the time of this database lock, 7 patients had completed Week 10 or early termination assessments but not Week 22 assessments.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 16/207 (7.7%) | 29/207 (14%) |
| Vedolizumab | — | 13/209 (6.2%) | 25/209 (12%) |
| Event | Placebo | Vedolizumab |
|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 11/207 | 2/209 |
| Abdominal painGastrointestinal disorders | 1/207 | 1/209 |
| DehydrationMetabolism and nutrition disorders | 1/207 | 0/209 |
| PolyarthritisMusculoskeletal and connective tissue disorders | 1/207 | 0/209 |
| General physical health deteriorationGeneral disorders | 1/207 | 0/209 |
| DemyelinationNervous system disorders | 1/207 | 0/209 |
| UrticariaSkin and subcutaneous tissue disorders | 1/207 | 0/209 |
| PancreatitisGastrointestinal disorders | 0/207 | 1/209 |
| Small intestinal obstructionGastrointestinal disorders | 0/207 | 1/209 |
| Gastric ulcerGastrointestinal disorders | 0/207 | 1/209 |
| Event | Placebo | Vedolizumab |
|---|---|---|
| HeadacheNervous system disorders | 15/207 | 11/209 |
| PyrexiaGeneral disorders | 13/207 | 7/209 |
| NauseaGastrointestinal disorders | 5/207 | 12/209 |
The Overall Intent-to-treat (ITT) Population consisted of all randomized participants who received any amount of blinded study drug.
| Age, Continuous(years) | Placebo | Vedolizumab | Total |
|---|---|---|---|
| Mean | 37.1 ± 13.15 | 38.6 ± 12.14 | 37.9 ± 12.66 |
| Age, Customized(participants) | Placebo | Vedolizumab | Total |
|---|---|---|---|
| < 35 years | 105 | 88 | 193 |
| ≥ 35 years | 102 | 121 | 223 |
| Age, Customized(participants) | Placebo | Vedolizumab | Total |
|---|---|---|---|
| < 65 years | 202 | 206 | 408 |
| ≥ 65 years | 5 | 3 | 8 |
| Sex: Female, Male(Participants) | Placebo | Vedolizumab | Total |
|---|---|---|---|
| Female | 118 | 118 | 236 |
| Male | 89 | 91 | 180 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Vedolizumab | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 8 |
| Not Hispanic or Latino | 199 | 204 | 403 |
| Unknown or Not Reported | 4 | 1 | 5 |
| Race/Ethnicity, Customized(participants) | Placebo | Vedolizumab | Total |
|---|---|---|---|
| White | 186 | 188 | 374 |
| Black | 5 | 4 | 9 |
| Asian | 9 | 9 | 18 |
| Other | 7 | 6 | 13 |
| Not Reported | 0 | 2 | 2 |
| Body Weight(kg) | Placebo | Vedolizumab | Total |
|---|---|---|---|
| Mean | 71.3 ± 19.22 | 69.5 ± 17.76 | 70.4 ± 18.50 |
| Body Mass Index(kg/m^2) | Placebo | Vedolizumab | Total |
|---|---|---|---|
| Mean | 24.6 ± 6.13 | 24.0 ± 5.13 | 24.3 ± 5.65 |
15 further baseline measures are reported on the registry.
The record gives a start of Nov 2010, a primary completion of Feb 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 2 years 5 months after primary completion. A results delay was requested in Mar 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab
Millennium Pharmaceuticals, Inc. →